EMA Committee for Orphan Medicinal Products
The Committee for Orphan Medicinal Products (COMP) is a scientific committee within the EMA responsible for reviewing orphan drug designation applications.
Orphan designation applies to medicines for rare diseases and provides regulatory and economic benefits, such as market exclusivity and reduced fees.
The COMP assesses the medical relevance and potential of these medicines before their development and market entry in Europe.
